Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 6/20 | 0.43 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462334 | 0.93 | EGFR (0.43) | RETSYKEGFRNOTUMPRKCQ | |
| SCHEMBL14482192 | 0.83 | SYK (0.40) | RETSYKEGFRMAPT | |
| SCHEMBL15887163 | 0.83 | MAPT (0.41) | MAPT | |
| SCHEMBL12462088 | 0.83 | MAPT (0.48) | MAPT | |
| SCHEMBL1580038 | 0.83 | MAPT (0.40) | EGFRMAPT | |
| SCHEMBL2166734 | 0.83 | MEN1 (0.48) | RETSYKEGFRMAOA | |
| SCHEMBL2217677 | 0.83 | NPC1 (0.47) | MAPT | |
| SCHEMBL2216004 | 0.82 | MAPT (0.40) | SYKERBB2MAPT | |
| SCHEMBL12462012 | 0.82 | TP53 (0.46) | SYKMAPT | |
| SCHEMBL2219260 | 0.82 | MEN1 (0.42) | SYKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| EP-2523956-A1 | ANTI - INFECTIVE PYRIDO (1,2 -A) PYRIMIDINES | Institut Pasteur Korea (KR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011085990-A1 | ANTI - INFECTIVE PYRIDO (1,2 -A) PYRIMIDINES | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011085990-A1 | ANTI - INFECTIVE PYRIDO (1,2 -A) PYRIMIDINES | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | TYMS, TYMP, DCTPP1 | RET 4465/4885SYK 2095/4885EGFR 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.